Wondfo Finecare™ POCT Vitamin D Test Validated by Independent Clinical Study

Peer-reviewed research published in the International Journal of General Medicine (2026) demonstrates strong analytical agreement and diagnostic concordance between Wondfo Finecare™ and benchmark automated CLIA platforms.

Accurate assessment of vitamin D status is increasingly vital across primary care, outpatient services, and clinical laboratory medicine. In a peer-reviewed study published in the International Journal of General Medicine (2026), independent researchers evaluated the fluorescence-based point-of-care immunoassay Wondfo Finecare™ alongside two established automated chemiluminescent immunoassay (CLIA) platforms, including the market-benchmark DiaSorin LIAISON® system.

The study provides compelling clinical evidence demonstrating high analytical correlation and diagnostic agreement between these platforms, supporting the expanded role of decentralized point-of-care testing (POCT) in routine vitamin D management.
 

Why Faster Access to Vitamin D Testing Matters

Vitamin D deficiency remains a prevalent global health concern, directly linked to skeletal disorders, metabolic dysfunction, and immune system dysregulation. While high-throughput automated CLIA analyzers remain the primary solution for centralized laboratories, their traditional workflow requires specialized infrastructure, batch processing, and longer sample-to-result turnaround times.

As modern healthcare systems pivot toward preventive screening and decentralized chronic disease management, clinical decision-makers require diagnostic solutions that deliver lab-comparable reliability directly at the point of care—without compromising analytical rigor.
 

Independent Clinical Validation Across a Diverse Patient Cohort

To rigorously evaluate real-world performance, the study evaluated 311 human serum samples spanning the complete clinical spectrum of vitamin D concentrations—from severe deficiency to sufficiency. To mirror complex clinical practice, the cohort intentionally included high-risk populations, such as pregnant women, patients with chronic kidney disease (CKD), and individuals with osteoporosis.

Key Analytical Highlights
•  Strong Correlation with Market Benchmark: When evaluated against the benchmark DiaSorin LIAISON® analyzer, Wondfo Finecare™ achieved a very strong analytical correlation (Spearman r = 0.92)—the highest correlation observed among all platform comparisons in the study.
•  Minimal Method Bias: Agreement analysis demonstrated a mean bias of -4.18% with no evidence of proportional error. The authors noted this falls comfortably within the College of American Pathologists (CAP) acceptability criteria for vitamin D accuracy assessment.
•  Excellent Diagnostic Agreement: Using the standard clinical threshold for vitamin D insufficiency (25(OH)D < 30 ng/mL), the Finecare™ platform demonstrated outstanding diagnostic accuracy compared to the laboratory benchmark:
-  AUC: 0.982
-  Overall Concordance: 93% (Cohen's κ = 0.85)
-  Specificity: 96%
-  Negative Predictive Value (NPV): 96%

Figure: Receiver Operating Characteristic (ROC) curves evaluating diagnostic performance for vitamin D insufficiency (25(OH)D < 30ng/mL) across platforms (Finecare vs. DiaSorin AUC = 0.982).

Bridging Laboratory Performance and Point-of-Care Workflow

Beyond numerical precision, the study underscores the practical operational benefits of decentralized immunoassay testing:
•  Speed & Flexibility: The Wondfo Finecare™ system utilizes a competitive fluorescence immunoassay architecture, delivering quantitative results in approximately 10 minutes.
•  Sample Versatility: Supports multiple sample types, including whole blood, serum, or plasma, eliminating mandatory pre-analytical centrifugation delays in primary care settings.
•  Clinical Utility: While automated CLIA systems excel in high-volume core labs, Finecare™ enables rapid, lab-comparable clinical decision-making in outpatient clinics, community health centers, urgent care, and remote facilities.
 

Supporting Broader Access to Routine Screening

The study conclusions confirm that the Wondfo Finecare™ fluorescence immunoassay provides favorable analytical agreement with automated CLIA analyzers and robust diagnostic performance for routine 25(OH)D classification. These peer-reviewed findings reinforce its potential to expand access to rapid, decentralized vitamin D screening across diverse healthcare environments.
 

As healthcare providers seek to expand access to routine vitamin D assessment beyond centralized laboratories, independent clinical evidence plays an increasingly important role in technology evaluation. This study contributes additional peer-reviewed data supporting the application of fluorescence-based point-of-care testing in appropriate clinical settings.

Explore the Wondfo Finecare™ Solution
To learn more about Wondfo Finecare™ analyzers and our Vitamin D testing solution, please visit:
[ Explore Wondfo Finecare™ & Vitamin D Solution ] Vitamin D Rapid Quantitative Test Solutions | POCT Vitamin D Diagnostics – Wondfo
[ View Finecare™ Product Details ]Wondfo Finecare FIA Meters (Point of Care Testing)
Interested in partnering with us or requesting the full clinical paper?
Contact Wondfo Biotech - Wondfo